Page 108 - 《中国药房》2023年15期

[21] SCOTT ALGOOD H M. T cell cytokines impact epithelial [30] HOISNARD L，PINA VEGAS L，DRAY-SPIRA R，et al.
cell responses during Helicobacter pylori infection[J]. J Risk of major adverse cardiovascular and venous thrombo‐
Immunol，2020，204（6）：1421-1428. embolism events in patients with rheumatoid arthritis ex‐
[22] SPAGNOLO P，DISTLER O，RYERSON C J，et al. posed to JAK inhibitors versus adalimumab：a nationwide
Mechanisms of progressive fibrosis in connective tissue cohort study[J]. Ann Rheum Dis，2023，82（2）：182-188.
disease （CTD） -associated interstitial lung diseases [31] OZEN G，PEDRO S，MICHAUD K. The risk of cardio‐
（ILDs）[J]. Ann Rheum Dis，2021，80（2）：143-150. vascular events associated with disease-modifying anti‐
[23] MIRA-AVENDANO I，ABRIL A，BURGER C D，et al. rheumatic drugs in rheumatoid arthritis[J]. J Rheumatol，
Interstitial lung disease and other pulmonary manifesta‐ 2021，48（5）：648-655.
tions in connective tissue diseases[J]. Mayo Clin Proc， [32] BUXEDA A，REDONDO-PACHÓN D，PÉREZ-SÁEZ M
2019，94（2）：309-325. J，et al. Sex differences in cancer risk and outcomes after
[24] PUNDOLE X，SUAREZ-ALMAZOR M E. Cancer and kidney transplantation[J]. Transplant Rev，2021，35（3）：
rheumatoid arthritis[J]. Rheum Dis Clin North Am，2020， 100625.
46（3）：445-462. [33] GRULICH A E，VAN LEEUWEN M T，FALSTER M O，
[25] CURTIS J R，SARSOUR K，NAPALKOV P，et al. Inci‐ et al. Incidence of cancers in people with HIV/AIDS com‐
dence and complications of interstitial lung disease in pared with immunosuppressed transplant recipients：a
users of tocilizumab，rituximab，abatacept and anti-tumor meta-analysis[J]. Lancet，2007，370（9581）：59-67.
necrosis factor α agents，a retrospective cohort study[J]. [34] DE GERMAY S，BAGHERI H，DESPAS F，et al. Abata‐
Arthritis Res Ther，2015，17：319. cept in rheumatoid arthritis and the risk of cancer：a world
[26] KANG E H，JIN Y Z，DESAI R J，et al. Risk of exacerba‐ observational post-marketing study[J]. Rheumatology，
tion of pulmonary comorbidities in patients with rheuma‐ 2020，59（9）：2360-2367.
toid arthritis after initiation of abatacept versus TNF in‐ [35] WADSTRÖM H，FRISELL T，ASKLING J，et al. Malig‐
hibitors：a cohort study[J]. Semin Arthritis Rheum，2020， nant neoplasms in patients with rheumatoid arthritis
50（3）：401-408. treated with tumor necrosis factor inhibitors，tocilizumab，
[27] SUISSA S，HUDSON M，DELL’ANIELLO S，et al. Com‐ abatacept，or rituximab in clinical practice：a nationwide
parative safety of abatacept in rheumatoid arthritis with cohort study from Sweden[J]. JAMA Intern Med，2017，
COPD：a real-world population-based observational study 177（11）：1605-1612.
[J]. Semin Arthritis Rheum，2019，49（3）：366-372. [36] SIMON T A，BOERS M，HOCHBERG M，et al. Compara‐
[28] LEE Y K，AHN G Y，LEE J，et al. Excess mortality per‐ tive risk of malignancies and infections in patients with
sists in patients with rheumatoid arthritis[J]. Int J Rheum rheumatoid arthritis initiating abatacept versus other bio‐
Dis，2021，24（3）：364-372. logics：a multi-database real-world study[J]. Arthritis Res
[29] CARBONE F，BONAVENTURA A，LIBERALE L，et al. Ther，2019，21（1）：228.
Atherosclerosis in rheumatoid arthritis：promoters and op‐ （收稿日期：2022-11-29 修回日期：2023-07-13）
ponents[J]. Clin Rev Allergy Immunol，2020，58（1）：1-14. （编辑：胡晓霖）

· 1890 · China Pharmacy 2023 Vol. 34 No. 15 中国药房 2023年第34卷第15期